Mesna Altan (Mesna)

Mesna releases sulfhydryl groups that chemically bind the toxic metabolite acrolein, which is generated during the metabolism of cyclophosphamide and ifosfamide. By neutralising acrolein, Mesna prevents it from damaging the urothelium and causing hemorrhagic cystitis.

The dose of Mesna Altan is determined by the prescribing clinician based on the chemotherapy regimen, patient weight, renal function, and treatment protocol. Healthcare professionals calculate the appropriate amount and schedule for each individual case.

Safety data for Mesna in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Mesna Altan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mesna is the standard uroprotective agent for cyclophosphamide and ifosfamide‑induced cystitis because it directly inactivates acrolein. Other agents, such as sodium thiosulfate, are used for different toxicities and lack the specific acrolein‑binding mechanism that makes Mesna uniquely effective for these chemotherapies.

Mesna Altan must be stored at 2‑8 °C, protected from light, and should not be frozen or shaken. Keep the solution in its original packaging until use to maintain stability and potency.

Mesna Altan is given as an intravenous infusion. The infusion is typically administered before, during, and after the chemotherapy dose according to the specific protocol recommended by the treating oncologist.

The most serious risks include severe allergic reactions such as anaphylaxis, hemolysis, and rare cases of severe hypotension or pulmonary edema. Prompt medical attention is required if any of these symptoms develop during or after infusion.

Patients with known hypersensitivity to mesna or any of its excipients should avoid the product. Caution is also advised for individuals with severe renal impairment, uncontrolled electrolyte disturbances, or those who are pregnant or breastfeeding without a clear clinical justification.